# Thierry André

Source: https://onco.cc/people/thierry-andre/  
OnCo record `thierry-andre` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer.

## Summary

Thierry André (Hôpital Saint-Antoine, Paris) was principal investigator of MOSAIC, the trial that established oxaliplatin-based adjuvant chemotherapy for stage III colon cancer, and two decades later of KEYNOTE-177, which showed pembrolizumab doubles progression-free survival versus chemotherapy in MSI-high metastatic colorectal cancer. He also led CheckMate 8HW (nivolumab plus ipilimumab) and the IDEA collaboration on three versus six months of adjuvant therapy. He remains a leading GERCOR investigator.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: colorectal; immunotherapy; adjuvant
- Role: Professor of Medical Oncology, Sorbonne University; Head of Medical Oncology, Hôpital Saint-Antoine, Paris
- Specialisms: Colorectal cancer; Adjuvant chemotherapy; MSI-high immunotherapy; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Institut Universitaire de Cancérologie AP-HP Sorbonne Université](https://onco.cc/institutions/iuc-aphp-sorbonne/)
- trials: [CheckMate 8HW](https://onco.cc/trials/checkmate-8hw/), [KEYNOTE-177](https://onco.cc/trials/keynote-177/)
- key papers: [Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)](https://onco.cc/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/), [KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer](https://onco.cc/key-papers/paper-keynote-177-nejm-2020/), [Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142)](https://onco.cc/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/), [Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)](https://onco.cc/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/), [Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)](https://onco.cc/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/), [Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)](https://onco.cc/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/thierry-andre.json